Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
F-star Therapeutics, Inc. (SBPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/09/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of F-star Therapeutics, Inc",
"Amended and Restated Bylaws of F-star Therapeutics, Inc"
03/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma"
03/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
02/23/2023 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
02/09/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
12/30/2022 8-K Quarterly results
12/29/2022 8-K Quarterly results
12/21/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: "F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update"
01/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration Cambridge, United Kingdom and Cambridge, Mass. - January 05, 2022—F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on an..."
11/12/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "F-star Therapeutics to Present at The Society for Immunotherapy of Cancer 2021 Conference Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s FS120 First-in-Class OX40/CD137 Tetravalent Dual T Cell Agonist in Combination with Anti-PD-1 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass.- November 12, 2021— F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that the Company is participating in the 36th annual Society for Immunotherapy of Cancer 2021 Conference, taking place November 12-14 in Washington, D.C...",
"0.001 0.01 0.1 1 10 100 0 2000 4000 6000 8000"
11/10/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., November 10, 2021 - F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced third quarter 2021 financial results and a corporate update. Eliot Forster, CEO of F-star Therapeutics, Inc., said, “A year on from listing on NASDAQ, we have delivered on our planned milestones, and through them value for patients, partners and our investors. Our agile, tenacious approach, working with world-leading investigators, continues to further F-star’s mission to b...",
"H2 2021 H1 2022 H2 2022 H2 2023 H1 2023 FS222 FS120 SB 11285 FS118"
10/20/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass. — October 20, 2021 — F-star Therapeutics, Ltd. , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecifi..."
08/12/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., August 12, 2021 — F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces second quarter 2021 financial results and provides a corporate update. The Company today announces an expanded clinical development strategy for FS118, F-star's first-in-class bispecific antibody targeting LAG-3 and PD-L1, into checkpoint inhibitor naïve patients. This new study with FS118 is in biomarker enriched subsets of patients with non-small cell lung cancer and diffuse...",
"Slides"
07/14/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors July 8, 2021 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 — F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it has entered into an exclusive licensing agreement with AstraZeneca plc , under which AstraZeneca will receive global rights to research, develop and commercialize next generation Stimulator of Interferon Genes inhibitor compounds. Under the terms of the agreement, AstraZeneca is granted exclusive access to F-star's novel preclinical STING inhibitors. AstraZeneca will be responsible for all future researc..."
06/04/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, UK and CAMBRIDGE, MA, March 29, 2021 — F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces 2020 full-year financial results and provides corporate update. 2020 was a year of transformation for F-star. The Company successfully listed on NASDAQ and advanced multiple programs into the clinic. F-star also presented Phase 1 data on its most advanced program FS118, and dosed patients in two additional clinical trials with FS222 and FS120. The Company continued to deliver on its long-term collaborations and e..."
02/05/2021 8-K/A Quarterly results
01/04/2021 8-K Quarterly results
12/04/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial"
11/25/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222"
11/20/2020 8-K Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra...
Docs: "Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation of the Company",
"Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation of the Company",
"Executive Service Agreement, as amended July 22, 2020, by and between F-star Biotechnology Limited and Eliot Forster, Ph.D",
"Consulting Agreement, by and between F-star Therapeutics LLC and Darlene Deptula-Hicks",
"Service Agreement, by and between F-star Biotechnology Limited and Neil Brewis, Ph.D",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"Form of Indemnification Agreement, by and between F-star Therapeutics, Inc. and each of its directors and executive officers",
"STING Agonist Contingent Value Rights Agreement, by and between Spring Bank Pharmaceuticals, Inc., F-star Therapeutics Limited, Computershare Inc., Computershare Trust Company, N.A., and the Holder Representative",
"STING Antagonist Contingent Value Rights Agreement, by and between Spring Bank Pharmaceuticals, Inc., F-star Therapeutics Limited, Computershare Inc., Computershare Trust Company, N.A., and the Holder Representative",
"Letter from RSM US LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy